Nolvadex

$160.00

INDICATIONS

Metastatic breast cancer

NOLVADEX (tamoxifen citrate) is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, NOLVADEX (tamoxifen citrate) is an alternative to oophorectomy or radiation therapy to the ovaries. Available data indicate that patients whose tumors are estrogen receptor positive are more likely to benefit from NOLVADEX (tamoxifen citrate) treatment.

Adjuvant breast cancer treatment

NOLVADEX (tamoxifen citrate) is indicated for the treatment of node-positive breast cancer in women after total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some adjuvant studies with NOLVADEX (tamoxifen citrate), the greatest benefit to date was in the subgroup with four or more positive axillary nodes.

NOLVADEX (tamoxifen citrate) is indicated for the treatment of axillary node negative breast cancer in women after total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.

The estrogen and progesterone receptor levels can help predict whether adjuvant treatment with NOLVADEX (tamoxifen citrate) is likely to be beneficial.

NOLVADEX (tamoxifen citrate) reduces the occurrence of contralateral breast cancer in patients receiving adjuvant NOLVADEX (tamoxifen citrate) therapy for breast cancer.